A
Annalisa Chiarenza
Researcher at University of Catania
Publications - 129
Citations - 4350
Annalisa Chiarenza is an academic researcher from University of Catania. The author has contributed to research in topics: Chronic lymphocytic leukemia & Medicine. The author has an hindex of 26, co-authored 108 publications receiving 3590 citations. Previous affiliations of Annalisa Chiarenza include Columbia University.
Papers
More filters
Journal ArticleDOI
Analysis of the coding genome of diffuse large B-cell lymphoma
Laura Pasqualucci,Vladimir Trifonov,Giulia Fabbri,Jing Ma,Davide Rossi,Annalisa Chiarenza,Victoria A. Wells,Adina Grunn,Monica Messina,Oliver Elliot,Joseph M. Chan,Govind Bhagat,Amy Chadburn,Gianluca Gaidano,Charles G. Mullighan,Raul Rabadan,Riccardo Dalla-Favera +16 more
TL;DR: By combining next-generation sequencing and copy number analysis, it is shown that the DLBCL coding genome contains, on average, more than 30 clonally represented gene alterations per case and novel dysregulated pathways underlying its pathogenesis are identified.
Journal ArticleDOI
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci,David Dominguez-Sola,Annalisa Chiarenza,Giulia Fabbri,Adina Grunn,Vladimir Trifonov,Lawryn H. Kasper,Stephanie Lerach,Hongyan Tang,Jing Ma,Davide Rossi,Amy Chadburn,Vundavalli V. Murty,Charles G. Mullighan,Gianluca Gaidano,Raul Rabadan,Paul K. Brindle,Riccardo Dalla-Favera +17 more
TL;DR: The results identify CREBBP/EP300 mutations as a major pathogenetic mechanism shared by common forms of B-cell non-Hodgkin’s lymphoma, with direct implications for the use of drugs targeting acetylation/deacetylation mechanisms.
Journal ArticleDOI
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Lydia Scarfò,Thomas Chatzikonstantinou,Gian Matteo Rigolin,Giulia Quaresmini,Marina Motta,Candida Vitale,José A. García-Marco,Jose Angel Hernandez-Rivas,Fatima Miras,Mónica Baile,Juan Marquet,Carsten Utoft Niemann,Gianluigi Reda,Talha Munir,Eva Gimeno,Monia Marchetti,Francesca Maria Quaglia,Marzia Varettoni,Julio Delgado,Sunil Iyengar,Ann Janssens,Roberto Marasca,Angela Ferrari,Carolina Cuéllar-García,Gilad Itchaki,Martin Spacek,Lorenzo De Paoli,Luca Laurenti,Mark-David Levin,Enrico Lista,Francesca Romana Mauro,Martin Simkovic,Ellen van der Spek,Elisabeth Vandenberghe,Livio Trentin,Ewa Wasik-Szczepanek,Rosa Ruchlemer,Dominique Bron,Maria Rosaria De Paolis,Giovanni Del Poeta,Lucia Farina,Myriam Foglietta,Massimo Gentile,Yair Herishanu,Tobias Herold,Ozren Jakšić,Arnon P. Kater,Sabina Kersting,Lara Malerba,Lorella Orsucci,Viola Maria Popov,Paolo Sportoletti,Mohamed A. Yassin,Barbara Pocali,Gábor Barna,Annalisa Chiarenza,Gimena Dos Santos,Eugene Nikitin,Martin Andres,Maria Dimou,Michael Doubek,Alicia Enrico,Yervand K Hakobyan,Olga Kalashnikova,Macarena Ortiz Pareja,Maria Papaioannou,Davide Rossi,Nimish Shah,Amit Shrestha,Oana Stanca,Niki Stavroyianni,Vladimir Strugov,Constantine S. Tam,Mihnea Zdrenghea,Marta Coscia,Kostas Stamatopoulos,Giuseppe Rossi,Alessandro Rambaldi,Emili Montserrat,Robin Foà,Antonio Cuneo,Paolo Ghia +81 more
TL;DR: In CLL, COVID-19 severity increases with age; antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
Journal ArticleDOI
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Davide Rossi,Lodovico Terzi-di-Bergamo,Lorenzo De Paoli,Michaela Cerri,Guido Ghilardi,Annalisa Chiarenza,Pietro Bulian,Carlo Visco,Francesca Romana Mauro,Fortunato Morabito,Agostino Cortelezzi,Francesco Zaja,Francesco Forconi,Francesco Forconi,Luca Laurenti,Ilaria Del Giudice,Massimo Gentile,Iolanda Vincelli,Marina Motta,Marta Coscia,Gian Matteo Rigolin,Alessandra Tedeschi,Antonino Neri,Roberto Marasca,Omar Perbellini,Carol Moreno,Giovanni Del Poeta,Massimo Massaia,Pier Luigi Zinzani,Marco Montillo,Antonio Cuneo,Valter Gattei,Robin Foà,Gianluca Gaidano +33 more
TL;DR: The majority of very low-risk patients remained free of progression after treatment and their hazard of relapse decreased after 4 years from FCR, indicating that neither the disease nor complications of its treatment affected survival in this favorable CLL group.
MOLECULAR PREDICTION OF DURABLE REMISSION AFTER FIRST LINE FLUDARABINE-CYCLOPHOSPHAMIDE-RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA Running title: Durable remission after FCR
Davide Rossi,Lodovico Terzi-di-Bergamo,Lorenzo De Paoli,Michaela Cerri,Annalisa Chiarenza,Pietro Bulian,C. Visco,Francesca Romana Mauro,Agostino Cortelezzi,Francesco Zaja,Francesco Forconi,Luca Laurenti,Massimo Gentile,Iolanda Vincelli,Marina Motta,Antonino Neri,Roberto Marasca,C Moreno,Pier Luigi Zinzani,Antonio Cuneo,V. Gattei,S. Maria Misericordia,Spedali Civili,S. Anna,Sant Pau,G. Gaidano +25 more
TL;DR: Davide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, Michaela Cerri, Guido Ghilardi, Annalisa Chiarenza, Pietro Bulian, Carlo Visco, Francesca R. Mauro, Fortunato Morabito, Agostino Cortelezzi, Francesco Zaja, Forconi, Luca Laurenti, Ilaria Del Giudice, Massimo Gentile, Iolanda Vincelli, Marina Motta, Marta Coscia, Gian Matteo Rigolin,A